4-Nitrobenzoyl chloride is a yellow crystalline solid that is used as a reagent in organic synthesis. It is a versatile building block for the preparation of various functionalized compounds. Its importance stems from its reactivity towards nucleophiles, making it suitable for acylation reactions. It is studied extensively due to its applications in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. For example, it is used in the synthesis of the anti-inflammatory drug ibuprofen. 4-Nitrobenzoyl chloride can be synthesized through the reaction of 4-nitrobenzoic acid with thionyl chloride. It is a strong electrophile and can react with various nucleophiles, such as alcohols, amines, and thiols. 4-Nitrobenzoyl chloride is a useful reagent for the preparation of amides, esters, and other carbonyl compounds. The presence of the nitro group makes it more reactive than benzoyl chloride. This increased reactivity is due to the electron-withdrawing nature of the nitro group. In addition, 4-nitrobenzoyl chloride can be used as a starting material for the synthesis of other useful compounds, such as 4-nitrobenzoic acid and 4-nitroaniline. 4-Nitrobenzoyl chloride is a versatile and important reagent in organic synthesis, and its applications continue to be explored.'
ID Source | ID |
---|---|
PubMed CID | 8502 |
CHEMBL ID | 1599838 |
SCHEMBL ID | 43141 |
SCHEMBL ID | 16692347 |
MeSH ID | M0127354 |
Synonym |
---|
122-04-3 |
benzoyl chloride, 4-nitro- |
nsc5381 |
p-nitrobenzoic acid chloride |
benzoyl chloride, p-nitro- |
p-nitrobenzoyl chloride |
nsc-5381 |
4-nitrobenzoyl chloride |
nitrobenzoyl chloride, 4- |
inchi=1/c7h4clno3/c8-7(10)5-1-3-6(4-2-5)9(11)12/h1-4 |
NCGC00091803-01 |
4-nitro-benzoyl chloride |
ai3-08914 |
brn 0473192 |
ccris 3136 |
nsc 5381 |
einecs 204-517-4 |
4-nitrobenzoic acid chloride |
4-nitrobenzoyl chloride, 98% |
N0176 |
A804833 |
NCGC00091803-02 |
x3h8pw2gc4 , |
4-09-00-01191 (beilstein handbook reference) |
unii-x3h8pw2gc4 |
ec 204-517-4 |
dtxcid905742 |
cas-122-04-3 |
NCGC00257691-01 |
tox21_200137 |
dtxsid9025742 , |
STL163544 |
BBL012202 |
AKOS005716884 |
FT-0619215 |
CHEMBL1599838 |
SCHEMBL43141 |
4-nitrobenzoyl chloride [mi] |
nitrobenzoyl chloride, p- |
p-nitro- benzoyl chloride |
p-nitro-benzoyl chloride |
4-nitrobenzoylchloride |
4 -nitrobenzoyl chloride |
4-nitro-benzoylchloride |
para-nitrobenzoic acid chloride |
4-nitro benzoic acid chloride |
para-nitrobenzoyl chloride |
p-nitro-benzoylchloride |
4-nitro-benzoyl-chloride |
rho-nitrobenzoyl chloride |
4--nitrobenzoyl chloride |
4-nitro benzoyl chloride |
paranitrobenzoyl chloride |
4-nitrobenzoyi chloride |
p-nitrobenzoylchloride |
4-nitroberizoyl chloride |
STR01076 |
W-108439 |
F2190-0076 |
4-nitrobenzoyl chloride, for hplc derivatization, >=99.0% (gc) |
SCHEMBL16692347 |
mfcd00007345 |
EN300-18044 |
Q27293518 |
4-nitrobenzoyl-d4chloride |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 1.0000 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.8477 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
AR protein | Homo sapiens (human) | Potency | 40.1469 | 0.0002 | 21.2231 | 8,912.5098 | AID1259247; AID743040 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 5.3487 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 0.0061 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 60.0133 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (37.50) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (42.47) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (12.50%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |